+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Benign Prostatic Hyperplasia Therapeutics Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Benign Prostatic Hyperplasia Therapeutics Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Benign Prostatic Hyperplasia Therapeutics Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6081737
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Benign Prostatic Hyperplasia (BPH) represents a common urological condition affecting a significant proportion of the male population over the age of 50. Characterized by the noncancerous enlargement of the prostate gland, BPH often leads to lower urinary tract symptoms such as increased frequency, urgency and nocturia, which can substantially impair quality of life. Over recent decades, therapeutic strategies have diversified beyond monotherapies to include combination treatments and novel drug classes targeting smooth muscle relaxation and hormonal pathways.

The current therapeutic landscape is shaped by a growing emphasis on patient-centric care, with a focus on optimizing efficacy while minimizing adverse events. Advances in molecular understanding and drug delivery technologies have spurred innovation in both established and emerging modalities. Concurrently, regulatory shifts and international trade policies are influencing market access and pricing dynamics, prompting stakeholders to adapt strategies across research, development, manufacturing and distribution.

This executive summary provides a concise yet comprehensive overview of the key factors driving the BPH therapeutics market, including transformative shifts in treatment paradigms, the cumulative impact of recent tariff implementations, and critical insights into market segmentation, regional performance and leading corporate players. Actionable recommendations are offered to guide industry leaders in navigating this evolving environment.

Transformative Shifts Reshaping BPH Treatment Paradigms

In response to increasing patient demand for personalized regimens, the BPH market has undergone several transformative shifts. First, the expansion of therapeutic classes beyond traditional alpha blockers and 5-alpha reductase inhibitors has introduced combination medications, pairing alpha blockers with either 5-alpha reductase inhibitors or phosphodiesterase-5 inhibitors to simultaneously address gland enlargement and smooth muscle tone. This dual-action approach enhances symptom relief and may reduce progression risk.

Second, the advent of selective receptor modulators and targeted delivery systems has improved tolerability profiles, leading to higher adherence rates. For instance, Type 2 5-alpha reductase inhibitors demonstrate comparable efficacy to nonselective agents but with a reduced incidence of sexual dysfunction. Similarly, selective alpha blockers distinguish themselves through preferential binding to receptor subtypes, minimizing cardiovascular side effects.

Lastly, digital health integration-leveraging telemedicine and mobile applications-has begun to streamline patient monitoring, symptom tracking and prescription adjustments. This holistic shift toward data-driven care facilitates proactive management of BPH, ultimately enhancing patient outcomes and reinforcing the importance of real-world evidence in shaping therapeutic guidelines.

Cumulative Impact of United States Tariffs on BPH Therapeutics

The imposition of new United States tariffs in 2025 has created both challenges and opportunities within the BPH therapeutics sector. Pharmaceutical manufacturers that rely on imported active pharmaceutical ingredients (APIs) and excipients now face escalated input costs, which can compress profit margins or necessitate price adjustments. In particular, combination medication producers and companies utilizing specialized delivery technologies have reported sourcing constraints that could delay product launches and disrupt supply chains.

Conversely, these tariff measures have incentivized domestic API production and strengthened local supplier partnerships. Stakeholders with vertically integrated operations are better positioned to mitigate cost fluctuations and maintain competitive pricing. Additionally, the protectionist environment has catalyzed strategic alliances between multinational firms and regional contract manufacturing organizations, fostering technology transfer and capacity expansion.

While end consumers may experience short-term price pressures, the long-term effect is likely to be a more resilient supply network. By diversifying sourcing strategies and investing in domestic manufacturing, companies can secure uninterrupted access to critical raw materials and reinforce their market positions amid global trade uncertainties.

Key Segmentation Insights Driving Market Differentiation

A nuanced understanding of market segmentation is crucial for tailoring product development and commercial strategies. Based on therapeutic class, the market encompasses 5-alpha reductase inhibitors, alpha blockers, combination medications and phosphodiesterase-5 inhibitors with further distinctions between Type 1 and Type 2 inhibitors, nonselective and selective alpha blockers, and oral phosphodiesterase-5 inhibitors. In terms of administration route, patient convenience drives demand for oral formulations alongside emerging injectable and intravenous options designed for rapid onset.

The distinction between over-the-counter versus prescription drugs reflects varying regulatory frameworks and patient autonomy, while formulation types span liquid dosage forms such as syrups, semi-solid gels and ointments, and solid capsules and tablets. Demographically, age stratification into below 50 years, 50-60 years and above 60 years cohorts informs targeted messaging, and consideration of pre-existing conditions like diabetes underscores the importance of personalized risk-benefit analyses. Distribution channels range from hospital and retail pharmacies to online platforms, and end-user environments include clinics, home care settings and hospitals, each presenting unique access pathways and operational considerations.

Integrating these segmentation dimensions supports a comprehensive go-to-market approach by aligning product features, pricing and promotional tactics with specific patient and provider needs.

Critical Regional Insights Influencing Market Dynamics

Regional dynamics reveal heterogeneous growth trajectories and unmet needs across global markets. In the Americas, robust healthcare infrastructure and extensive insurance coverage facilitate rapid adoption of combination therapies and novel drug classes. However, pricing pressures and reimbursement negotiations remain pivotal factors shaping market penetration.

In Europe, Middle East & Africa, regulatory harmonization efforts and multilateral procurement initiatives are enhancing access while controlling costs. Countries within this region demonstrate variable preferences for selectivity in alpha blockers and route of administration, reflecting divergent clinical guidelines and patient expectations.

The Asia-Pacific region exhibits significant demand driven by aging populations and rising awareness of BPH management options. Market expansion is further supported by government-led screening programs and growing private healthcare expenditure. However, supply chain complexities and regional tariff policies require proactive localization strategies to ensure consistent product availability.

Across these regions, companies that adapt their portfolios to local regulatory environments and patient demographics can capitalize on distinct growth opportunities.

Leading Companies Shaping the BPH Therapeutics Sphere

The competitive landscape is characterized by both established pharmaceutical giants and agile niche players driving innovation. AbbVie Inc., Allergan plc and Astellas Pharma Inc. lead with differentiated portfolios that include selective alpha blockers and combination regimens. Eli Lilly and Company and Pfizer Inc. contribute to the pipeline with novel phosphodiesterase-5 inhibitors, while Merck & Co., Inc. and Johnson & Johnson leverage their manufacturing scale to optimize cost efficiencies.

Specialized firms such as Progenics Pharmaceuticals, Inc. and Endo Pharmaceuticals Inc. focus on targeted delivery systems, and Dr. Reddy’s Laboratories Ltd. and Sun Pharmaceutical Industries Ltd. strengthen their presence through generic approvals and cost-competitive formulations. Global players including Bayer AG, GlaxoSmithKline PLC, Sanofi S.A. and Teva Pharmaceutical Industries Ltd. diversify across both prescription and over-the-counter segments, ensuring broad market coverage. Regional companies like Apotex Inc., Ipsen S.A., Mylan N.V. and Zydus Cadila reinforce localized strategies through partnerships and tailored offerings.

Leadership in this sector hinges on aligning R&D investments with evolving clinical guidelines, maintaining robust supply chains and executing differentiated commercialization plans.

Actionable Recommendations for Industry Leadership

Industry leaders should prioritize three strategic initiatives to secure sustainable growth. First, strengthening vertical integration through partnerships or acquisitions of domestic API and formulation manufacturers can mitigate the impact of trade-related cost volatility while enhancing supply resilience. Second, investing in real-world evidence and digital health platforms will facilitate data-driven decision-making, improve patient adherence monitoring and support differentiated value propositions in reimbursement discussions.

Third, refining segmentation strategies by leveraging demographic insights-such as focusing on patients above 60 years with comorbid conditions-will enable more targeted marketing and clinical trial designs. By tailoring formulations and dosing regimens to specific subpopulations, companies can address unmet needs, reduce adverse event profiles and foster deeper physician engagement.

Collectively, these actions will empower stakeholders to navigate competitive pressures, regulatory complexities and evolving patient expectations.

Conclusion: Navigating Growth in an Evolving BPH Market

The benign prostatic hyperplasia therapeutics market stands at a pivotal juncture, shaped by evolving treatment paradigms, regulatory landscapes and global trade dynamics. Organizations that embrace integrated supply chain strategies, leverage robust real-world data and deploy precise segmentation will thrive in this complex environment.

By aligning product innovation with patient-centric objectives and regional market requirements, industry leaders can capture new opportunities and reinforce their competitive advantages. Continuous collaboration with healthcare providers, patient advocacy groups and regulatory agencies will further enhance market responsiveness and drive sustained growth.

Market Segmentation & Coverage

This research report categorizes the Benign Prostatic Hyperplasia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • 5-alpha Reductase Inhibitors
    • Type 1 Inhibitors
    • Type 2 Inhibitors
  • Alpha Blockers
    • Non-selective Alpha Blockers
    • Selective Alpha Blockers
  • Combination Medications
    • Alpha Blocker and 5-alpha Reductase Inhibitor Combination
    • Alpha Blocker and Phosphodiesterase-5 Inhibitor Combination
  • Phosphodiesterase-5 Inhibitors
    • Oral Inhibitors
  • Injection
  • Intravenous
  • Oral
  • Over-the-counter Drugs
  • Prescription Drugs
  • Liquid Dosage Forms
    • Syrups
  • Semi-solid Dosage Forms
    • Gels
    • Ointments
  • Solid Dosage Forms
    • Capsules
    • Tablets
  • Age
    • 50-60 Years
    • Above 60 Years
    • Below 50 Years
  • Pre-existing Conditions
    • Diabetes
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Clinics
  • Home Care Settings
  • Hospitals

This research report categorizes the Benign Prostatic Hyperplasia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Benign Prostatic Hyperplasia Therapeutics Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • Apotex Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Endo Pharmaceuticals Inc.
  • GlaxoSmithKline PLC
  • Ipsen S.A.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan N.V.
  • Pfizer Inc.
  • Progenics Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Benign Prostatic Hyperplasia Therapeutics Market, by Therapeutic Class
8.1. Introduction
8.2. 5-alpha Reductase Inhibitors
8.2.1. Type 1 Inhibitors
8.2.2. Type 2 Inhibitors
8.3. Alpha Blockers
8.3.1. Non-selective Alpha Blockers
8.3.2. Selective Alpha Blockers
8.4. Combination Medications
8.4.1. Alpha Blocker and 5-alpha Reductase Inhibitor Combination
8.4.2. Alpha Blocker and Phosphodiesterase-5 Inhibitor Combination
8.5. Phosphodiesterase-5 Inhibitors
8.5.1. Oral Inhibitors
9. Benign Prostatic Hyperplasia Therapeutics Market, by Route of Administration
9.1. Introduction
9.2. Injection
9.3. Intravenous
9.4. Oral
10. Benign Prostatic Hyperplasia Therapeutics Market, by Drug Type
10.1. Introduction
10.2. Over-the-counter Drugs
10.3. Prescription Drugs
11. Benign Prostatic Hyperplasia Therapeutics Market, by Formulation Type
11.1. Introduction
11.2. Liquid Dosage Forms
11.2.1. Syrups
11.3. Semi-solid Dosage Forms
11.3.1. Gels
11.3.2. Ointments
11.4. Solid Dosage Forms
11.4.1. Capsules
11.4.2. Tablets
12. Benign Prostatic Hyperplasia Therapeutics Market, by Patient Demography
12.1. Introduction
12.2. Age
12.2.1. 50-60 Years
12.2.2. Above 60 Years
12.2.3. Below 50 Years
12.3. Pre-existing Conditions
12.3.1. Diabetes
13. Benign Prostatic Hyperplasia Therapeutics Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Benign Prostatic Hyperplasia Therapeutics Market, by End-user
14.1. Introduction
14.2. Clinics
14.3. Home Care Settings
14.4. Hospitals
15. Americas Benign Prostatic Hyperplasia Therapeutics Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. AbbVie Inc.
18.3.2. Allergan plc
18.3.3. Amgen Inc.
18.3.4. Apotex Inc.
18.3.5. Astellas Pharma Inc.
18.3.6. Bayer AG
18.3.7. Dr. Reddy’s Laboratories Ltd.
18.3.8. Eli Lilly and Company
18.3.9. Endo Pharmaceuticals Inc.
18.3.10. GlaxoSmithKline PLC
18.3.11. Ipsen S.A.
18.3.12. Johnson & Johnson
18.3.13. Merck & Co., Inc.
18.3.14. Mylan N.V.
18.3.15. Pfizer Inc.
18.3.16. Progenics Pharmaceuticals, Inc.
18.3.17. Sanofi S.A.
18.3.18. Sun Pharmaceutical Industries Ltd.
18.3.19. Teva Pharmaceutical Industries Ltd.
18.3.20. Zydus Cadila
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY TYPE 1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY TYPE 2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY NON-SELECTIVE ALPHA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SELECTIVE ALPHA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKER AND 5-ALPHA REDUCTASE INHIBITOR COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKER AND PHOSPHODIESTERASE-5 INHIBITOR COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ORAL INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SYRUPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY AGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 50-60 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ABOVE 60 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY BELOW 50 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PRE-EXISTING CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PRE-EXISTING CONDITIONS, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PRE-EXISTING CONDITIONS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PRE-EXISTING CONDITIONS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PRE-EXISTING CONDITIONS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 107. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 108. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 109. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 110. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 111. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 112. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 114. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 115. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 116. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 117. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 118. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 119. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 120. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PRE-EXISTING CONDITIONS, 2018-2030 (USD MILLION)
TABLE 121. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 124. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 125. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 126. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 127. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 128. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 130. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 131. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 132. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 133. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 134. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 135. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 136. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PRE-EXISTING CONDITIONS, 2018-2030 (USD MILLION)
TABLE 137. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 142. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PRE-EXISTING CONDITIONS, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 156. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 157. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 158. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 159. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 160. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 161. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 164. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PRE-EXISTING CONDITIONS, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 173. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 174. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 175. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 176. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 177. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 178. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 180. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 181. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 182. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 183. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 184. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 185. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 186. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PRE-EXISTING CONDITIONS, 2018-2030 (USD MILLION)
TABLE 187. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 189. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 190. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 191. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 192. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 193. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 194. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 196. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 197. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 198. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 199. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 200. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 201. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 202. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PRE-EXISTING CONDITIONS, 2018-2030 (USD MILLION)
TABLE 203. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 205. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 206. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 207. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 208. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 209. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 210. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 212. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 213. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 214. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 215. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 216. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 217. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 218. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PRE-EXISTING CONDITIONS, 2018-2030 (USD MILLION)
TABLE 219. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. INDONESIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 222. INDONESIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 223. INDONESIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 224. INDONESIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 225. INDONESIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 226. INDONESIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. INDONESIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 228. INDONESIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 229. INDONESIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 230. INDONESIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 231. INDONESIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 232. INDONESIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 233. INDONESIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 234. INDONESIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PRE-EXISTING CONDITIONS, 2018-2030 (USD MILLION)
TABLE 235. INDONESIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. INDONESIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 237. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 238. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 239. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 240. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 241. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 242. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 244. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 245. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 246. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 247. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 248. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 249. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 250. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PRE-EXISTING CONDITIONS, 2018-2030 (USD MILLION)
TABLE 251. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 253. MALAYSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 254. MALAYSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 255. MALAYSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 256. MALAYSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 257. MALAYSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 258. MALAYSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 259. MALAYSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 260. MALAYSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 261. MALAYSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 262. MALAYSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 263. MALAYSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 264. MALAYSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 265. MALAYSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 266. MALAYSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PRE-EXISTING CONDITIONS, 2018-2030 (USD MILLION)
TABLE 267. MALAYSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. MALAYSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 269. PHILIPPINES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE

Companies Mentioned

  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • Apotex Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Endo Pharmaceuticals Inc.
  • GlaxoSmithKline PLC
  • Ipsen S.A.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan N.V.
  • Pfizer Inc.
  • Progenics Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila

Methodology

Loading
LOADING...

Related Topics

Related Reports

Benign Prostatic Hyperplasia (BPH) Drugs - Global Strategic Business Report - Product Image

Benign Prostatic Hyperplasia (BPH) Drugs - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Doxazosin Mesylate Extended Release Tablets Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Doxazosin Mesylate Extended Release Tablets Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global, United States Global, United States
From
Benign Prostatic Hyperplasia Treatment Market by Treatment Type (Medications, Minimally Invasive Therapies, Surgical Treatments), Product Type (Catheters, Electrodes, Implants), End User - Global Forecast 2025-2030 - Product Image

Benign Prostatic Hyperplasia Treatment Market by Treatment Type (Medications, Minimally Invasive Therapies, Surgical Treatments), Product Type (Catheters, Electrodes, Implants), End User - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Benign Prostatic Hyperplasia Treatment Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 96 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Global Market Report 2025 - Product Image

Benign Prostatic Hyperplasia Treatment Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.